Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

4077F Doc t-pa administration considered

Other

Also known as: tPA consideration, thrombolytic consideration

Performance measure indicating documentation that tissue plasminogen activator (tPA) administration was considered for stroke treatment. Tracks decision-making documentation.

In Plain Language

considering a clot-busting drug for stroke

Clinical Context

Quality measure for acute ischemic stroke care. Documents appropriate evaluation and consideration of thrombolytic therapy within treatment window.

RVU Information

CPT 4077F does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.

Billing & Documentation

Documentation should include the clinical indication, service details, and any applicable performance metrics. Coverage may vary by payer — verify acceptance before billing.

Specialties

NeurologyInternal MedicineEmergency Medicine

Frequently Asked Questions

What is CPT code 4077F?

CPT 4077F (Doc t-pa administration considered) is a Other code. Performance measure indicating documentation that tissue plasminogen activator (tPA) administration was considered for stroke treatment. Tracks decision-making documentation.

Who uses CPT code 4077F?

CPT 4077F is used by Neurology, Internal Medicine, Emergency Medicine. Quality measure for acute ischemic stroke care. Documents appropriate evaluation and consideration of thrombolytic therapy within treatment window.

When is CPT 4077F used?

Quality measure for acute ischemic stroke care. Documents appropriate evaluation and consideration of thrombolytic therapy within treatment window.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against national data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.